China’s TopRidge Pharma to Produce Sputnik V COVID-19 Vaccine

China’s TopRidge Pharma agreed to the production of more than 100 million doses of Russia’s two-shot Sputnik V vaccine against COVID-19.

The Russian Direct Investment Fund (RDIF) said on Thursday that they have agreed to cooperate for the production of the doses of vaccine.

“The Russian Direct Investment Fund and TopRidge Pharma (a subsidiary company of one of China’s pharmaceutical market leaders, Tibet Rhodiola Pharmaceutical Holding) have agreed to cooperate on the production of over 100 million doses per year of the world’s first registered vaccine against coronavirus Sputnik V in China,” the statement said.

TopRidge Pharma will also be able to distribute the vaccine in mainland China, Hong Kong, Macao, and Taiwan, however, it will be subject to “all appropriate regulatory approvals.”

According to the statement, the vaccine that will be produced will be enough to inoculate over 50 million people.

Lancet, one of the world’s “oldest and most respected” medical journals, confirmed that Sputnik V has an efficacy rate of 91.6 percent.

Sputnik V has also been registered in 58 countries globally.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.